Video
Dr. Choueiri on Ongoing Trials of Immunotherapy in RCC
Author(s):
Toni K. Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses some of the ongoing trials evaluating different immunotherapy agents in renal cell carcinoma.
Toni K. Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses some of the ongoing trials evaluating different immunotherapy agents in renal cell carcinoma (RCC).
Choueiri highlights one trial that is comparing a combination of nivolumab (Opdivo) plus ipilimumab (Yervoy) with sunitinib (Sutent) in patients with previously untreated metastatic RCC. Another trial is currently examining the efficacy of atezolizumab in combination with bevacizumab (Avastin) compared with sunitinib.
The takeaway message, according to Choueiri, is that the standard of care is constantly evolving. Clearly, the field is moving generally in the direction of combination treatments to treat patients with RCC.
